The Clinical Efficacy Observation Of Qingdai San For External Application In The Treatment Of Patients With Intermediate And Advanced Stage Of Primary Hepatic Carcinoma

Objective:This study is based on the experience of Professor Li Shijie who summarizes it from the clinical treatment of primary hepatic carcinoma.Its aim is to observe the clinical efficacy and safety of "Qingdai San" in the treatment of patients with intermediate and advanced Stage of primary hepatic carcinoma, and provide a further clinical basis for the treatment of primary hepatic carcinoma.Methods:According to the inclusion and exclusion criteria of this study,using randomized,controlled, single-blind trial therapy.In this study,46 patients with intermediate and advanced Stage of primary liver cancer were included,who were inpatient from March 2014 to February 2015 in Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.We divided 46 cases of patients into treatment group and control group. By observing, the changes before and after treatment in quality of life,T.C.M. symptoms,Child-Pugh classification,KPS score, cardiac liver and kidney functions,AFP, Blood coagulation function,adverse reactions of treatments and so on,we further studied the "Qingdai San" in the treatment of primary liver cancer, evaluated its clinical efficacy and safety.Results:Through statistical analyzing (SPSS 17.0),the study shows:(1)After the treatment,the PT、APTT of the patients in the treatment group extended, compared with the pretherapy and comparison who have statistical difference (P<0.05). The changes of AFP’s level in the blood don’t have significant difference between the two group(P>0.05).(2)Using "Qingdai San",the patients of the research had higher KPS score,improved the t.c.m symptoms,especially on hypochondriac pain、chest distress and sighing、anorexia、nausea and vomiting、splanchneurysma, compared with the control group which have statistical difference (P<0.05).(3)After the treatment,the patients of treatment group had been improved their quality of life, especially on physical functioning、symptoms/Side effects,and their self-assessments,Which has statistical difference between the two groups(P<0.05).(4)There was not significant difference between the two groups about Child-Pugh classification、clinical stages before and after treatment(P>0.05).(5)Four patients in the treatment group occured I grade of Local skin itch which is its main adverse reaction.However,it is not serious,and it can release by itself.Compared with the comparison in hematology,the treatment group doesn’t have conspicuous noxious property of the heart,liver and kidney,ect(P>0.05).Conclusion:For the patients with liver cancer, "Qingdai San" has a certain anti-coagulation, improve patients’quality of life and clinical symptoms to some extent.The "QingdaiSan" doesn’t have significant toxicity of heart,liver,kidney,and skin lesions. And the patients have good tolerance to it.In this study,the number of cases is limited.Expanding the number of cases and the observation time is necessary to get a more comprehensive and accurate evaluation on long-term effect and safety of the "Qingdai San".